While the vaccination campaign is playing an essential role in combating Covid-19, second-generation

monoclonal antibodies are becoming increasingly relevant and can make a significant contribution to
treating the disease.

"Vaccines have played and are playing a key role in helping us to come out of this very complex
situation."

"Vaccines are a very important part but only part of the solution. It is important to try to make available
all possible weapons to fight this pandemic. And there are additional tools that are giving extremely
encouraging results. There are many, but the most important ones are monoclonal antibodies. In
particular, the monoclonal antibodies, let's call them second-generation, which are not only proving to
be extremely effective but are also showing, in some cases, not all but in some cases, excellent
resistance to all the variations in the virus that are unfortunately beginning to be seen in some parts of
the world today".

In recent days, the European Commission has announced the first portfolio of drugs that could soon be
available for the treatment of Covid-19 patients. These include four monoclonal antibodies and an
immunosuppressant, including sotrovimab, the monoclonal antibody developed by Gsk in collaboration
with Vir Biotechnology, which has also received authorisation for temporary distribution in Italy, for the
treatment of patients affected by the Sars-CoV-2 virus.

"Sotrovimab is a particularly effective monoclonal antibody. All studies conducted so far have shown
significant efficacy equal to 85% reduction in hospitalisation and risk of death for all those using this
monoclonal antibody."

"It is just the latest news that in Abu Dhabi, where this monoclonal antibody is already used 97.3% of
patients had a substantial improvement within seven days of use."

"Now that the European Union has formally pronounced itself in favour of sotrovimab, the member
states can speed up significantly so that sotrovimab can be made available to patients in their respective
countries".

"In any case, in my opinion priority should be given to timing. I think it's very important that we move as
quickly as possible in Europe. Having a tool or a weapon like sotrovimab at home, ready to prevent
much more critical situations, I think is of paramount importance'.

Correction;
While the vaccination campaign is playing an essential role in combating Covid-19, second-generation
monoclonal antibodies are becoming increasingly relevant and can make a significant contribution to
treating the disease.

“Vaccines have played and are playing a key role in helping us to come out of this very complex
situation.”

“Vaccines are a very important part but only part of the solution. It is important to try to make available
all possible weapons to fight this pandemic. And there are additional tools that are giving extremely
encouraging results. There are many, but the most important ones are monoclonal antibodies. In
particular, the monoclonal antibodies, let’s call them second-generation, which are not only proving to
be extremely effective but are also showing, in some cases, not all but in some cases, excellent
resistance to all the variations in the virus that are unfortunately beginning to be seen in some parts of
the world today”.

In recent days, the European Commission has announced the first portfolio of drugs that could soon be
available for the treatment of Covid-19 patients. These include four monoclonal antibodies and an
immunosuppressant, including sotrovimab, the monoclonal antibody developed by Gsk in collaboration
with Vir Biotechnology, which has also received authorization for temporary distribution in Italy, for the
treatment of patients affected by the Sars-CoV-2 virus.

“Sotrovimab is a particularly effective monoclonal antibody. All studies conducted so far have shown
significant efficacy equal to 85% reduction in hospitalization and risk of death for all those using this
monoclonal antibody.”

“It is just the latest news that in Abu Dhabi, where this monoclonal antibody is already used 97.3% of
patients had a substantial improvement within seven days of use.”

“Now that the European Union has formally pronounced itself in favor of sotrovimab, the member
states can speed up significantly so that sotrovimab can be made available to patients in their respective
countries”.

“In any case, in my opinion, priority should be given to timing. I think it’s very important that we move
as quickly as possible in Europe. Having a tool or a weapon like sotrovimab at home, ready to prevent
much more critical situations, I think is of paramount importance.